Kornimate/medical-research-clean huggingface dataset:
gastric pathophysiology in diabetes

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Functional Dyspepsia; Gastroparesis; Healthy

Summary: this is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. the investigators aim to examine the stomach with various measurement devices to gain information about its different functions and malfunctions. after the initial measurements, the examinations will be repeated after a year in each patient. changes in the measurement values will be examined and their relations to each other and to the overall health of the patients will be investigated. for example it is hypothesised that diabetic patients also suffering from functional dyspepsia or gastroparesis will also show some changes in the function of the pyloric muscle.


Eligibility criteria:
inclusion criteria (diabetic group): * diabetes mellitus type i or ii, minimal duration of the disease 3 years, minimal duration of specific treatment (drugs, insulin) 2 years exclusion criteria (diabetic group): * diabetes mellitus type ii being treated with a diet only * severe acute decompensation of diabetes (uncontrolled diabetes) necessitating hospitalization * concomitant treatment with more than one prokinetic agent * active treatment with opioids or a history of treatment with opioids within 12 months before enrolment * previous esophageal or major gastric surgery (e.g. esophageal myotomy, esophagectomy, antireflux surgery, billroth i or ii gastric resection, gastric pull-through, pyloromyotomy, pyloroplasty, gastric electrical stimulation) * organic pyloric (or intestinal) obstruction (fibrotic stricture, etc.) * severe coagulopathy * esophageal or gastric varices and /or portal gastropathy * advanced liver cirrhosis * pregnancy or puerperium * malignant or pre-malignant gastric diseases (dysplasia, gastric cancer, gist): patients with a history of such disease after its cure are eligible for enrolment * the presence of a rumination syndrome or eating disorders (anorexia nervosa, bulimia). in case of doubts, a psychiatric examination will be performed. * systemic connective tissue disorder * inability to obtain informed consent * any other condition, which in the opinion of the investigator would interfere with study requirements
the efficacy and safety of om-89 in patients with recurrent chronic prostatitis/chronic pelvic pain syndrome

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Chronic Prostatitis; Chronic Pelvic Pain Syndrome

Summary: this study is planned to evaluate the efficacy and safety of om-89 in patients with recurrent chronic prostatitis/chronic pelvic pain syndrome (cp/cpps)

this clinical study is designed as a multicenter, randomized, placebo-controlled, double-blind, phase 4 study to evaluate the efficacy and safety of the combination therapy of uro-vaxom® capsule and alfuzosin in patients with recurrent chronic prostatitis. once a subject voluntarily gives written consent to participate in this study, a screening test will be conducted to evaluate their eligibility. subjects determined to be eligible to participate in the study on visit 2 (baseline) will be enrolled, randomized 1:1 either to the test group (om-89 \[uro-vaxom® capsule\]) or the control group (placebo of om-89) and administered the investigational product for 26 weeks. in parallel, an alpha blocker (alfuzosin 10 mg) will be administered for the first 13 weeks as a background treatment, followed by the placebo of alfuzosin until week 26. the efficacy and safety will be checked until week 52 from the start of the treatment for all subjects.

Eligibility criteria:
inclusion criteria: * male adults aged ≥19 to ≤55 at the time of obtaining the written consent * those who have t pain or discomfort in the pelvic or genital area * nih-cpsi (the national institutes of health chronic prostatitis symptom index) ≥ 15 in total score * voluntarily signed the informed consent form to participate in this study exclusion criteria: * prostate specific antigen (psa) ≥ 4.0 ng/ml at visit 1 (screening) * received a prostate biopsy, surgery, or treatment within 12 weeks before visit 1 (screening) * past or current medical history as herpes infection treatment within 1 year before the screening,treatment for genital infections or sexually transmitted diseases and history of urogenital tumors. * those who have a medication history of the drugs(drugs or health functional food, health functional foods that affect prostate function etc)or have a plan to receive them during the study at visit 1

Keywords: cp/cpps chronic prostatitis chronic pelvic pain syndrome
fusion targeted biopsy of the prostate

Conditions: Prostate Cancer

Summary: the objective of the proposed study is to evaluate a new, molecular image directed, three-dimensional (3d) ultrasound guided biopsy system in human patients. the current biopsy uses ultrasound imaging as guidance. however, the procedure uses two-dimensional (2d) ultrasound images and has sampling errors thus some cancers can be missed from the standard 2d image-guided biopsy. in this study, an fda-approved ultrasound device will be used to obtain three-dimensional (3d) images of the prostate from a commercially available ultrasound scanner. the clinician can use the 3d images to guide biopsy, record the core location of the biopsy sites, and perform re-biopsy to the same sites in a patient follow-up examination. this system can also use images from magnetic resonance imaging (mri) or positron emission tomography (pet) and then fuse pet or mr images with 3d ultrasound images to guide the needle to a suspicious tumor target as seen on mri or pet. we think that this fusion targeted biopsy technology will help to improve the accuracy of the current systematic biopsy approach for prostate cancer detection.


Eligibility criteria:
inclusion criteria: * patients must be 18 years or older * abnormal uptake in prostate necessitating a biopsy * able to provide informed consent exclusion criteria: * age less than 18 * cannot provide informed consent * less than 2 months since any prior prostate biopsy (to decrease false positive uptake from inflammation)
exploration of the reward system by functional mri in narco-cataplexy patients with and without rem sleep behavior disorder

Conditions: Narcolepsy; Cataplexy

Summary: up to 50% of narcolepsy-cataplexy (nc) patients suffer from rem sleep behavior disorder (rbd), a parasomnia. a strong link was found between rbd and impulse control disorders (icd) in parkinson disease (pd) patients. icd are thought to be related to a dysfunction of meso-cortico-limbic pathways which belong to the so called ''reward system''. a recent study in irmf shows that rbd is associated with impaired reward system. a strong link was found between these two disorders and therefore we believe that rbd is associated with impaired reward system in nc the main objective of this study is to evaluate differences in brain activation between nc patients with and without rbd. the investigators hypothesize that nc patients with rbd have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without rbd.

type of study: prospective, case control study. number of centers: 3 (clermont-ferrand, vichy and montlucon) patients : the study will be performed in 66 subjects (22 pd patients with rbd, 22 pd patients without rbd and 22 healthy volunteers, age-and sex-matched without any contraindications to perform an mri) study performance : during the first visit (baseline, inclusion visit, 2 hours), each subject will perform a clinical and neurological examination and neuropsychological assessment (depression by the beck depression inventory (bdi); apathy by the lille apathy rating scale (lars), impulsivity by the urgency, lack of premeditation, lack of perseverance, sensation seeking scale (upps)) eligible patients will be welcomed for a video polysomnography in the sleep center, for one night (month 1, 1 night) and in a subsequent visit at the mri department for the functional mri (month 1, 1 hour). this session will be of about 45 minutes. the reward system will be explore using an experimental task during functional magnetic resonance imaging (fmri). the name of this task is the"monetary incentive delay task".

Eligibility criteria:
inclusion criteria: * - men or women, right handed, 18 to 80 years * patients with type 1 narcolepsy according to the criteria of the international classification of sleep, 3rd version, 2014 * acceptance of the protocol and signature of a written consent * social security affiliation exclusion criteria: * previous history of psychosis or psychiatric disease * history of stroke or vascular lesion on mri. * perceptual disorder (vision, hearing) may hinder the realization of the protocols, * dementia defined by a score across montreal cognitive assessment (moca) \<26/30. * major depressive state defined by a score scale beck depression inventory (bdi)\> 14 * apathy defined by a score ≥ 14 on the apathy scale of starkstein. patients with a score ≥ this one will be excluded. * usual contraindications to mri, knowing that no contrast agent injection is performed. * pregnant woman.

Keywords: functional mri reward system rem sleep behaviour disorder narco-cataplexy
enhancing critical thinking competency and nursing quality in critically ill patient care

Conditions: Evidence-Based Nursing; Critically Ill Patient; Training

Summary: the ebn-based nutritional management protocol effectively enhances junior nurses' specialized critical thinking competency and improves patient nutritional outcomes and satisfaction, demonstrating its potential to optimize critical care quality. however, further validation through multicenter studies with larger cohorts, extended follow-up periods, and additional outcome measures is warranted.

this study aims to develop an evidence-based nursing (ebn)-based nutritional management protocol for critically ill patients and assess its effects on junior nurses' specialized critical thinking competency and nursing quality. a quasi-experimental design was employed, involving 7 junior nurses and 84 critically ill patients in each of the study and control groups. the study group implemented the ebn-based protocol alongside structured training, while the control group adhered to conventional practices. nursing quality outcomes included assessments of nurses' specialized critical thinking skills, patient nutritional biomarkers (serum albumin, prealbumin), complication rates (aspiration, diarrhea, abdominal distension), and patient satisfaction. multivariate binary logistic regression analysis identified influencing factors.

Eligibility criteria:
inclusion criteria: * diagnosis of critical illness by attending physicians or higher-qualified specialists according to established critical care diagnostic standards * requirement for icu admission with full access to standardized critical care and medical resources * preserved partial gastrointestinal function without severe intestinal obstruction or perforation confirmed by certified nutritionists or senior nurses, enabling potential enteral nutrition (en) or combined en-parenteral nutrition (pn) support. exclusion criteria: * patients with severe cognitive impairment or psychiatric instability (e.g., advanced dementia, schizophrenia, status epilepticus) impairing capacity to engage in nutritional assessments or adhere to clinical protocols, which would jeopardize data collection reliability * terminal-stage conditions (malignancies, renal/hepatic failure) with life expectancy \< 7 days or exclusively receiving palliative care, leading to misalignment between their palliative nutritional goals and the study's therapeutic intervention objectives * congenital metabolic disorders (e.g., phenylketonuria) or short bowel syndrome requiring specialized nutritional protocols, which were incompatible with conventional critical care nutritional protocols and could compromise the generalizability of study findings * pregnancy/lactation due to unique nutritional demands and potential risks to fetal/infant development inherent in the study design, contravening established ethical standards * cases involving transfer, voluntary discharge, or withdrawal of consent that compromised data completeness.
h. pylori testing for patients with non-specific upper abdominal pain in the emergency department

Conditions: Gastritis; Peptic Ulcer; Peptic Ulcer Perforation; Stomach Ulcer

Summary: this pilot study aims to estimate the prevalence of helicobacter pylori (h. pylori) colonization in patients presenting with non-specific abdominal pain (nsap) in an urban academic emergency department (ed) located in washington, dc.

the major goal is to study the prevalence of h. pylori using the 13c urea breath test (ubt) in emergency department (ed) patients with non-specific abdominal pain. the investigators plan to enroll 250 patients during the pilot stage of this study. this t2 translational trial aims to apply recommended guidelines for the investigation and management of nsap and dyspepsia into the practical arena of ed clinical care. the "test-and-treat" approach to symptomatic h. pylori infection has been endorsed by the american gastroenterological association (aga). patients who test positive for h. pylori by ubt will be treated with clarithromycin-based triple medication therapy as recommended by the american college of gastroenterology (acg) at the discretion of the treating physician. the rationale is that successful identification of h. pylori in the ed and initiation of treatment may reduce future risk of gastritis, gastric lymphoma, and gastric cancer, and is cost-effective through reduction of future healthcare costs and symptom severity. study subjects will be followed for medication compliance, resolution of symptoms, and ability to obtain outpatient follow-up. as part of this study, the investigators will be collecting important information on the ed evaluation of abdominal pain.

Eligibility criteria:
inclusion criteria: for any patient with chief complaint of "abd", "stom", "epig", "chest", "naus" "do you have pain or discomfort or burning in your upper abdomen as the main reason for coming to er today?" exclusion criteria: * the patient less than 18 years old. * patient does not speak english nor has reliable adult translator. * patient does not have capacity to give consent? (confused/intoxicated/etc.) * the patient currently is on antibiotics. * the patient currently is on a ppi. (eg. prilosec \[omeprazole\]), protonix \[pantoprazole\], prevacid \[lansoprazole\], aciphex \[rabeprazole\], nexium \[esomeprazole\] * the patient has taken bismuth or pepto-bismol today. * the patient is known to be or suspected to be pregnant. * the patient unable to walk to h.pylori breath test. * the patient had "recent" negative h.pylori test for same symptoms. * there an "obvious alternative cause" for pain (per attending).

Keywords: dyspepsia abdominal pain helicobacter pylori [c06.405.748.398] [c06.405.748.586] [c06.405.748.586.698] [c06.405.748.586.849]
prediction of risk of vascular structural damage in patients with large vessel vasculitis (lvv) based on pet/mra image evaluation system

Conditions: Large Vessel Vasculitis

Summary: large vessel vasculitis (lvv) causes vascular inflammation, leading to serious complications such as aneurysm formation and stroke. it is difficult to identify the inflammation of the vessel wall by the current imaging methods, thus affecting the timing of treatment and selection of treatment options. improved examination methods to determine disease activity are highly needed to guide treatment.

this study was designed to assess vascular wall inflammation in patients with large vessel vasculitis by positron emission tomography and magnetic resonance imaging (pet/mra). the study has a 12-month follow-up period. after completing the baseline clinical assessment, laboratory test and pet/mra assessment, the intervention protocol will be determined by clinicians. the patients will visit the clinic every 1-2 months according to their specific conditions. clinical assessment, laboratory test and pet/mra re-examination will be completed at 6 and 12 months after treatment.

Eligibility criteria:
inclusion criteria: 1. clinically suspected or confirmed lvv and willing to undergo pet/mra 2. compliance with long-term follow-up 3. sign informed consent. exclusion criteria: 1. patients with other serious cardiovascular and cerebrovascular diseases, malignant tumors, infectious diseases, severe renal insufficiency. 2. severe mental disorders, severe claustrophobia unable to cooperate with the examination. 3. patients equipped with cardiac pacemaker, artificial heart valve, ferromagnetic vascular clamp after vascular surgery, aneurysm clamp, artificial cochlea, insulin pump and other drug dosage control devices, steel nail plate and other metal internal fixation, artificial joint, electronic eye, artificial eye. 4. allergic to contrast medium. 5. pregnant or lactating women. withdrawal criteria: 1. any exclusion criteria emerged during patient follow-up. 2. voluntarily withdrew from the study.

Keywords: large vessel vasculitis pet mra suvmax tba
acceptability of zinc-fortified lipid-based nutrient supplements

Conditions: Malnutrition

Summary: the purpose of the study is to assess the acceptability of the two lipid-based nutrient supplement (lns) formulations containing no zinc and a high amount of zinc (10 mg zinc / 20 g dose of lns). the hypothesis is that both products will be equally accepted by children and mothers.

we plan to conduct a series of acceptability studies to: 1) assess the amounts of zinc-free and high-zinc lns consumed by children during direct observation, 2) compare their mothers' sensory assessments of the respective products, and 3) review maternal reports of their child feeding experiences during more prolonged home feeding trials.

Eligibility criteria:
inclusion criteria: * currently breast-feeding and consuming complementary foods for at least 30 d exclusion criteria: * height-for-age and weight-for height z-scores \<-3 with respect to who growth standards * edema * diarrhea and other diseases that could interfere with food intake * severe systemic illness * history of peanut allergy * history of anaphylaxis/serious allergic reaction infants meeting these criteria and their mother's will be invited to participate

Keywords: lipid-based nutrient supplement prevention of malnutrition prevention of micronutrient deficiencies zinc
evaluation of a nasal mask for the treatment of obstructive sleep apnea in new zealand

Conditions: Obstructive Sleep Apnea

Summary: currently, fisher and paykel healthcare (fph) is developing a new nasal mask. this investigation is designed to evaluate the performance of the trial nasal mask, focused specifically on how the different seal sizes will perform on obstructive sleep apnea participants who are currently on positive airway pressure therapy. participant's prescribed treatment pressure with their usual mask will be collected for 7 days ± 3 days prior to mask fitting with the trial nasal mask. they will then be issued with the trial nasal mask to use in-home for 14 days ± 4 days.


Eligibility criteria:
inclusion criteria: * aged 18+ * diagnosed with ostructive sleep apnea by a practicing physician or clinicans * existing nasal or nasal pillows user * prescribed positive airway pressure therapy (bi-level or continuous positive airway pressure (cpap) or automatic positive airway pressure (apap)) exclusion criteria: * inability to give informed consent * pregnant or think they may be pregnant * anatomical or physiological conditions making positive airway pressure therapy inappropriate (e.g unconsolidated facial fracture) * patients who are in a coma or decreased level of consciousness * current diagnosis of co2 retention * commercial drivers who are investigated by new zealand transport agency (nzta)
development and application of an artificial intelligence-driven accurate identification model for gastric cancer lymph node metastasis

Conditions: The Primary Focus of This Study is on Gastric Cancer

Summary: the clinical trial titled "development and application of an artificial intelligence-driven accurate identification model for gastric cancer lymph node metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (ai) technology. this study will develop an ai-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies. the trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and ai experts who will collaborate to create a robust and precise identification system. participants will undergo standard diagnostic procedures, and the ai model will analyze imaging and pathological data to predict lymph node involvement. by comparing the ai model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. this approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. the successful implementation of this ai-driven model could revolutionize the current standards of care and serve as a blueprint for integrating ai technologies in other cancer diagnoses and treatments.


Eligibility criteria:
inclusion criteria: 1. diagnosis of gastric cancer: confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent. 2. lymph node involvement: suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports. 3. age: patients aged 18 years or older. 4. performance status: an eastern cooperative oncology group (ecog) performance status of 0 to 2, indicating a functional status that allows participation in the study. 5. informed consent: ability to provide written informed consent to participate in the study. exclusion criteria: 1. pregnancy or lactation: pregnant or lactating women, due to potential risks to the fetus or infant. 2. severe comorbid conditions: presence of severe comorbid medical conditions that could interfere with the study or pose additional risks. 3. previous ai-driven diagnostic intervention: prior use of any ai-driven diagnostic models specifically for gastric cancer lymph node metastasis. 4. inability to comply: inability or unwillingness to comply with study procedures, including follow-up visits and data collection. 5. mental or cognitive impairment: conditions that impair the ability to provide informed consent or participate effectively in the study.